Roche expands long-term alliance with Sysmex
- Expanded alliance includes an agreement on eco social collaboration to jointly foster more sustainable diagnostic solutions, and the renewal of an agreement on hematology solutions for commercial and hospital laboratories, complementing the Roche Diagnostics portfolio
- 25-year partnership between Roche and Sysmex brings hematology testing innovations to laboratories and helps patients get access to routine hematology diagnostics solutions
The updated non-exclusive agreement also introduces a new area of collaboration with an additional eco-social agreement to jointly explore more sustainable diagnostic solutions. By taking their long-standing collaboration beyond the current portfolio, both companies are committed to pursue more sustainable solutions.
"We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions. Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow," said Matt Sause, CEO of Roche Diagnostics.
"We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration. Developing our partnerships in the field of diagnostics even further and addressing enduring eco-social challenges represents a significant milestone in advancing our alliance to the next level. Together, we firmly believe in making even greater contributions to our customers in laboratories and creating a sustainable society," said Kaoru Asano, President of Sysmex Corporation.
About the partnership
Roche and Sysmex entered into their commercial and R&D collaboration in 1998 and continuously expanded their strong partnership. In 2020, the two companies signed the Global Business Partnership Agreement to further expand their partnership and to improve customer experience. In 2023, with renewed terms and expanded scope, both companies confirm their long-standing partnership and their commitment to build a more sustainable future for society.
Roche is committed to supporting improvements in haematology testing, which helps patients with the diagnosis and management of blood diseases, as diverse as anaemia and leukaemia. In the European Union (EU) alone, approximately 80 million people are currently affected with blood disorders. The burden of blood disorders on European society is estimated at
About Roche
Founded in 1896 in
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] Engert et al. EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101(2): 115-208. doi: 10.3324/haematol.2015.136739.
For further information please contact
Euan Cameron, Head of Communications, Core Lab, Roche Diagnostics Solutions |
Karin Freyenmuth, Head of Communications, Roche Diagnostics Partnering |
View original content:https://www.prnewswire.com/news-releases/roche-expands-long-term-alliance-with-sysmex-301892121.html
SOURCE Roche